
A digital command center that matches patients to trials in minutes — not months. Cross-referencing eligibility against 12,847 live studies with lab-protocol specificity.
Data sourced from 47 clinical sites across 6 therapeutic areas, 2023–2025. N = 3,200 pre-screen records.
| Metric | Manual Process | Enroll Automated | Scope |
|---|---|---|---|
Time per patient pre-screen From pulling records to eligibility decision | 4–6 hours | 4.2 minutes | |
Criteria cross-referenced Inclusion/exclusion criteria checked per patient | 12–18 avg. | All 347 | |
Screen-failure rate Patients enrolled then found ineligible post-consent | 68% | 26% | |
Data entry errors Transcription and criterion misapplication rate | 1 in 11 records | < 0.2% | |
Coordinator hours per enrolled patient Total staff time from identification to enrollment | 23 hrs | 4 hrs | |
Audit-ready documentation Sponsor audit trail completeness | Manual assembly | Auto-generated | |
Diversity benchmark tracking FDA diversity enrollment goal monitoring | Quarterly reports | Real-time | |
Protocol amendment updates Time to propagate criteria changes across site | 5–14 days | < 2 hours |
* Screen-failure and time metrics validated against IRB-approved site audit logs. Automated figures represent median across Enroll deployments Q3 2024–Q1 2026.
Each layer applies protocol-grade logic — not keyword matching. The signal separates from static at every stage.
Not projections. Not case studies. These are median outcomes from 0 active sites as of Feb 2026.
We used to spend the first three weeks of every study just building the pre-screening spreadsheet. Enroll eliminated that entirely. Our coordinator hours per enrolled patient dropped from 23 to under 4.

The audit trail alone is worth it. Every match decision has criterion-level documentation. Our last FDA audit, the inspector asked how we generated the pre-screen log. When we showed them, they asked if they could share it with other sites.

Takes 4 minutes. Delivers a match score across 12,847 live trials. No commitment, no sales call — just the answer to whether a trial exists for your patient right now.